Quick Takeaways: Why It Matters? The FDA’s EUA for generic Nitenpyram Tablets creates an immediate, affordable, OTC treatment option for pet owners facing necrotizing worm (NWS) fly infestations in dogs, puppies, cats, and kittens ≥2 lb and ≥4 weeks old. This broadens access to a cost...
Quick Takeaways: Why It Matters? Unlike drugs that carry safety concerns or diminishing effectiveness, LIFU aims to provide a non-invasive alternative to nerve blocks and radiofrequency ablation without systemic exposure, which could reduce reliance on medications and invasive procedures. ...
Quick Takeaways: Why It Matters? At scale (100,000+ ER visits already), AI-assisted documentation can meaningfully cut admin time, speed chart closure, and let vets and scribes reallocate hours to procedures, decision‑making, and client communication, helping VEG differentiate ...
Quick Takeaways: Why It Matters? Merck Animal Health is doubling down on biodevices and automation in poultry by buying TARGAN, turning from a strategic investor into full owner of high-speed sexing and precision vaccination tech Source: Businesswire...
Quick Takeaways: Why It Matters? Ceva is using this deal to cement a differentiated position in swine health by owning Europe’s only commercial vaccine against swine dysentery, a disease that drives major losses in pig production. This will also deepen Ceva’s R&D pipeline and...
Quick Takeaways: Why It Matters? Cronus Pharma is bringing price competition to a key canine heart failure drug class by launching the first FDA‑approved bioequivalent chewable to Vetmedin, available nationwide through vet distributors. For the market, this should lo...
Quick Takeaways: Why It Matters? Viyash is using BioForLife as a front-end platform to scale its companion animal business in Europe, starting with Italy, one of the continent’s largest and fastest-growing pet health markets. Market-wise, the all-cash ...
Quick Takeaways: Why It Matters? This deal gives Merck Animal Health an early, exclusive window into a gene-therapy pipeline for chronic and age-related diseases in pets, while Rejuvenate Bio secures non-dilutive R&D support and a $6M financing round to advance its platform...
Featured Article Cover Story Product Launches Partnerships & Collaborations Key Industry Themes In This Issue Cosmos Health Expands Into Animal Health Product launch Cosmos Health plans to launch a veterinary version of C-Scrub Wash 4%, expanding its antimicrobial wash brand into anima...
Quick Takeaways: Why It Matters? VetrixBio is testing a dual-action osteoarthritis therapy that targets both pain (NGF/TrkA) and cartilage degradation (ADAMTS-5) in dogs, rather than just providing analgesia. The clinical data in aged Beagles shows a single...
